Entrar/Registro  
HOME SPANISH
 
Revista de la Asociación Dental Mexicana
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Revista de la Asociación Dental Mexicana >Year 2017, Issue 1


Fortin PL, Briend MS, Morales SD, Pombo MT, Osnaghi L
Expression of E-cadherin and epidermal growth factor in oral leukoplakia
Rev ADM 2017; 74 (1)

Language: Español
References: 22
Page: 32-39
PDF: 1315.90 Kb.


Full text




ABSTRACT

Introduction: Oral leukoplakia is defined as a white plaque that cannot be removed by scraping and cannot be classified as any other disease entity. They are potentially malignant lesions related to the presence of epithelial dysplasia. These preneoplastic changes can be detected histologically, as well as through techniques that demonstrate different changes at the molecular level. E-cadherin is a membrane glycoprotein that plays a major role in maintaining cell-cell adhesion, preserving structural integrity and the polarity of epithelial tissue. Epidermal growth factors are a group of bio-regulatory proteins, whose primary function is to control the cell cycle. The aim of this study is to identify and compare the parameters for histological and molecular markers for malignant transformation in oral leukoplakia. Material and methods: The study was observational and descriptive in design. Samples were selected from 26 oral leukoplakia biopsies, which were routinely evaluated for histology and stained with hematoxylin and eosin, then subjected to immunostaining with epidermal growth factor and E-cadherin, with the intensity of staining and changes in the expression of each marker being evaluated. Results: Of the 26 leukoplakia examined, 16 showed hyperplastic changes and 10 mild to moderate dysplastic changes. The expression of E-cadherin showed no significant changes in non-dysplastic leukoplakia, while a loss of expression was found in only those leukoplakias with high-grade dysplastic changes, which was consistent with the histological findings. In leukoplakia with epithelial dysplasia, the EGF expression was mild to moderate at the basal and suprabasal strata level. In the case of non-dysplastic leukoplakia, mild staining was apparent, primarily in the basal stratum. Conclusion: The markers studied provided us with evidence of early-stage molecular changes that corresponded to those observed in the histology present, which display early biological changes. However, their usefulness as prognostic markers is questionable. A longitudinal study based on a larger sample is needed in order to be able to confirm this conclusion.


Key words: Immunostaining, dysplasia, white lesions, premalignant.


REFERENCIAS

  1. Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology & Genetics. Head and neck tumours. World Health Organization Classification of Tumours. Lyon: IARC-press; 2005.

  2. Vázquez-Álvarez R, Fernández-González F, Gándara-Vila P, Reboiras-López D, García-García A, Gándara-Rey JM. Correlation between clinical and pathologic diagnosis in oral leukoplakia in 54 patients. Med Oral Patol Oral Cir Bucal. 2010; 15 (6): e832-e838.

  3. Martínez-Sahuquillo Márquez A, Gallardo-Castillo I, Cobos-Fuentes MJ, Caballero-Aguilar J, Bullón-Fernández P. La leucoplasia oral. Su implicación como lesión precancerosa. Av Odontoestomatol. 2008; 24 (1): 33-44.

  4. Martorell-Calatayud A, Botella-Estrada R, Bagán-Sebastián JV, Sanmartín-Jiménez O, Guillén-Barona C. La leucoplasia oral: definición de parámetros clínicos, histopatológicos y moleculares y actitud terapéutica. Actas Dermosifiliogr. 2009; 100 (8): 669-684.

  5. Escribano-Bermejo M, Bascones-Martínez A. Leucoplasia oral: conceptos actuales. Av Odontoestomatol. 2009; 25 (2): 83-97.

  6. Schliephake H. Prognostic relevance of molecular markers of oral cancer-a review. Int J Oral Maxillofac Surg. 2003; 32 (3): 233-245.

  7. Santos-García A, Abad-Hernández MM, Fonseca-Sánchez E, Julián-González R, Galindo-Villardón P, Cruz-Hernández JJ et al. Expresión de E-cadherina, laminina y colágeno IV en la evolución de displasia a carcinoma epidermoide oral. Med Oral Patol Oral Cir Bucal. 2006; 11 (2): 100-105.

  8. Cornejo-Uribe R. El factor de crecimiento epidérmico y la diferenciación celular del epitelio mamario. Int J Morphol. 2011; 29 (3): 821-824.

  9. Díaz A, Lage A. Terapias con inhibidores del receptor del factor de crecimiento epidérmico: acercando el futuro. Biotecnología Aplicada. 2007; 24 (1): 1-9.

  10. Yarom N, Marginean C, Moyana T, Gorn-Hondermann I, Birnboim HC, Marginean H et al. EGFR expression variance in paired colorectal cancer primary and metastatic tumors. Cancer Biol Ther. 2010; 10 (5): 416-421.

  11. Sarkis SA, Abdullah BH, Abdul Majeed BA, Talabani NG. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol. 2010; 2: 13.

  12. Sridevi U, Jain A, Nagalaxmi V, Kumar UV, Goyal S. Expression of E-cadherin in normal oral mucosa, in oral precancerous lesions and in oral carcinomas. Eur J Dent. 2015; 9 (3): 364-372.

  13. Cruz MC, Pereira AL, Lopes FF, Nonaka CF, Silva RR, Freitas-Rde A et al. Immunohistochemical expression of E-cadherin and CD44v6 in squamous cell carcinomas of the lower lip and tongue. Braz Dent J. 2009; 20 (1): 64-69.

  14. Mahomed F, Altini M, Meer S. Altered E-cadherin/b-catenin expression in oral squamous carcinoma with and without nodal metastasis. Oral Dis. 2007; 13 (4): 386-392.

  15. Chaw SY, Majeed AA, Dalley AJ, Chan A, Stein S, Farah CS. Epithelial to mesenchymal transition (EMT) biomarkers--E-cadherin, beta-catenin, APC and Vimentin--in oral squamous cell carcinogenesis and transformation. Oral Oncol. 2012; 48 (10): 997-1006.

  16. Yogesh T, Narayan T, Shreedhar B, Shashidara R, Leekymohanty. The expression of E-cadherin and cathepsin-D in normal oral mucosa, oral epithelial dysplasia and oral squamous cell carcinoma: A comparative analysis between immunohistochemistry and routine histopathology. J Oral Maxillofac Pathol. 2011; 15 (3): 288-294.

  17. Diniz-Freitas M, García-Caballero T, Antúnez-López J, Gándara-Rey JM, García-García A. Reduced E-cadherin expression is an indicator of unfavourable prognosis in oral squamous cell carcinoma. Oral Oncol. 2006; 42 (2): 190-200.

  18. Jyothi Meka N, Ugrappa S, Velpula N, Kumar S, Naik-Maloth K, Kodangal S et al. Quantitative immunoexpression of EGFR in oral potentially malignant disorders: oral leukoplakia and oral submucous fibrosis. J Dent Res Dent Clin Dent Prospects. 2015; 9 (3): 166-174.

  19. Srinivasan M, Jewell SD. Quantitative analysis of PCNA, c-myc, EGFR and TGF-α in oral submucous fibrosis- an immunohistochemical study. Oral Oncol. 2001; 37 (5): 461-467.

  20. Kobayashi H, Kumagai K, Gotoh A, Eguchi T, Yamada H, Hamada Y et al. Upregulation of epidermal growth factor receptor 4 in oral leukoplakia. Int J Oral Sci. 2013; 5 (1): 14-20.

  21. Ribeiro DC, Gleber-Netto FO, Sousa SF, Bernardes VF, Guimaraes-Abreu MHN, Ferreira-Aguiar MC. Immunohistochemical expression of EGFR in oral leukoplakia: association with clinico-pathological features and cellular proliferation. Med Oral Patol Oral Cir Bucal. 2012; 17 (5): 739-744.

  22. Díaz-Prado S, Gallego-Guadalupe A, López-Cedrún JL, Ferreras-Granado J, Antón-Aparicio L. La ciclooxigenasa-2 (COX-2) y el factor de crecimiento epidérmico (EFG) en lesiones epiteliales orales premalignas. Rev Esp Cirug Oral y Maxilofac. 2009; 31 (3): 170-181.






>Journals >Revista de la Asociación Dental Mexicana >Year 2017, Issue 1
 

· Journal Index 
· Links 






       
Copyright 2019